Vanguard Group Inc. Has $307.48 Million Holdings in Progyny, Inc. (NASDAQ:PGNY)

Vanguard Group Inc. raised its holdings in shares of Progyny, Inc. (NASDAQ:PGNY) by 1.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,270,153 shares of the company’s stock after buying an additional 112,549 shares during the quarter. Vanguard Group Inc. owned about 8.57% of Progyny worth $307,484,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. HighTower Advisors LLC bought a new stake in shares of Progyny during the third quarter valued at approximately $512,000. Acadian Asset Management LLC bought a new stake in shares of Progyny during the third quarter valued at approximately $53,000. Federated Hermes Inc. increased its position in shares of Progyny by 16.5% during the third quarter. Federated Hermes Inc. now owns 26,648 shares of the company’s stock valued at $907,000 after purchasing an additional 3,771 shares during the period. Northern Trust Corp increased its position in shares of Progyny by 1.3% during the third quarter. Northern Trust Corp now owns 1,166,806 shares of the company’s stock valued at $39,695,000 after purchasing an additional 15,208 shares during the period. Finally, PEAK6 Investments LLC bought a new stake in shares of Progyny during the third quarter valued at approximately $288,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PGNY. Canaccord Genuity Group lowered their price objective on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. KeyCorp cut Progyny from an “overweight” rating to a “sector weight” rating in a research report on Friday, May 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $48.00 price target on shares of Progyny in a research report on Thursday, May 16th. BTIG Research lowered their price target on Progyny from $50.00 to $41.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Finally, Truist Financial lowered their price target on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a research report on Friday, May 17th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Progyny has a consensus rating of “Moderate Buy” and a consensus price target of $43.11.

Progyny Trading Down 0.0 %

NASDAQ:PGNY opened at $28.61 on Friday. Progyny, Inc. has a 1-year low of $23.90 and a 1-year high of $44.95. The business’s 50-day moving average price is $28.62 and its two-hundred day moving average price is $34.20. The firm has a market capitalization of $2.72 billion, a price-to-earnings ratio of 46.90, a PEG ratio of 1.86 and a beta of 1.46.

Progyny (NASDAQ:PGNY) last released its earnings results on Thursday, May 9th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.03. Progyny had a return on equity of 11.61% and a net margin of 5.53%. The firm had revenue of $278.08 million for the quarter, compared to analyst estimates of $289.41 million. During the same quarter in the prior year, the firm posted $0.18 earnings per share. The company’s quarterly revenue was up 7.6% on a year-over-year basis. Sell-side analysts predict that Progyny, Inc. will post 0.73 earnings per share for the current year.

Insider Buying and Selling at Progyny

In other Progyny news, CFO Mark S. Livingston sold 11,165 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $37.62, for a total value of $420,027.30. Following the transaction, the chief financial officer now owns 50,119 shares of the company’s stock, valued at $1,885,476.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, CFO Mark S. Livingston sold 11,165 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $37.62, for a total transaction of $420,027.30. Following the sale, the chief financial officer now owns 50,119 shares of the company’s stock, valued at $1,885,476.78. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Chairman David J. Schlanger sold 1,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $37.52, for a total value of $37,520.00. Following the sale, the chairman now directly owns 83,631 shares in the company, valued at approximately $3,137,835.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,075 shares of company stock valued at $842,254. 12.30% of the stock is currently owned by company insiders.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.